This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ICN, Ribapharm Tiff Resumes

The sniping between ICN Pharmaceuticals (ICN) and its takeover target Ribapharm (RNA) resumed Wednesday, as ICN accused its fellow drug company of hinting that ICN's buyout offer might go higher.

"We want to be absolutely clear. Our $6.25 per-share cash tender offer is final," said Robert W. O'Leary, ICN's chairman and chief executive, in a prepared statement.

The offer had been raised on Monday to $6.25 a share from $5.60 a share for the 20% of Ribapharm's shares than ICN doesn't own.

ICN argued that Ribapharm -- whose board of directors has declared both offers "inadequate" -- speculated in an Aug. 5 filing with the Securities and Exchange Commission that the buyout price could go higher.

Ribapharm recounted to the SEC the history of the buyout negotiations, noting that its board -- with one dissenter -- agreed to the new terms by removing a poison pill and allowing shareholders to vote on the ICN offer. If two-thirds of the Ribapharm shareholders support the sweetened bid, the board will accept the offer. When the new offer was announced, ICN said 53% of Ribapharm shareholders had agreed to tender for the original price. However, the SEC filing says, Ribapharm's board reiterated its belief that the $6.25 bid is "inadequate." The company said that if the two-thirds vote isn't secured by the new deadline of Aug. 19, "it is possible, though not certain, that ICN might be willing to increase the offer price further."

The SEC filing reveals there was considerable negotiating on a new buyout price, noting that ICN "conveyed that it would withdraw" its offer unless a deal could be settled by Aug. 4.

ICN proposed raising the offer to $5.80 and then to $6.10 on the condition that Ribapharm's board would endorse the deal. Then, on Monday, the company agreed to the terms of $6.25 a share and a two-thirds shareholder vote in return for Ribapharm's withdrawing its poison pill. The agreement raised ICN's buyout cost to $188 million from $168 million. Both companies are based in Costa Mesa, Calif.

ICN spun off Ribapharm as a public company in April 2002, initially keeping 83% of Ribapharm's shares. In early June, ICN said it would make a cash tender offer for the rest of Ribapharm's shares. Ribapharm's board rejected the offer and enacted a poison pill takeover defense that would be triggered when any company acquired 89.9% of the company's shares. ICN sued to block the poison pill.

In midmorning trading Wednesday, ICN's stock was down 2.1%, or 32 cents, at $15.48. Ribapharm's stock was up 1 cent at $6.15.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs